Showing 1 - 5 results of 5 for search 'A. Garfall', query time: 0.02s Refine Results
  1. 1
    PB2013: TECLISTAMAB COMPARED WITH REAL-WORLD THERAPIES IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA

    PB2013: TECLISTAMAB COMPARED WITH REAL-WORLD THERAPIES IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA by A. Krishnan, A. K. Nooka, A. Chari, A. Garfall, T. Martin, S. Nair, X. Lin, K. Qi, A. Londhe, L. Pei, E. Ammann, R. Kobos, J. Smit, T. Parekh, M. Slavcev, S. Usmani

    Published 2022-06-01
    Get full text
    Article
  2. 2
    S184: EVALUATING TECLISTAMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA FOLLOWING EXPOSURE TO OTHER B-CELL MATURATION ANTIGEN (BCMA)-TARGETED AGENTS

    S184: EVALUATING TECLISTAMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA FOLLOWING EXPOSURE TO OTHER B-CELL MATURATION ANTIGEN (BCMA)-TARGETED AGENTS by C. Touzeau, A. Krishnan, P. Moreau, A. Perrot, S. Z. Usmani, S. Manier, M. Cavo, C. Martinez-Chamorro, A. Nooka, T. Martin, L. Karlin, X. Leleu, N. Bahlis, B. Besemer, L. Pei, R. Verona, S. Girgis, C. Uhlar, R. Kobos, A. Garfall

    Published 2022-06-01
    Get full text
    Article
  3. 3
    P921: UPDATED EFFICACY AND SAFETY RESULTS OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1

    P921: UPDATED EFFICACY AND SAFETY RESULTS OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC... by J. Martínez-López, P. Moreau, S. Z. Usmani, A. Garfall, N. W. van de Donk, J. F. San-Miguel, A. Oriol, A. Chari, L. Karlin, M.-V. Mateos, R. Popat, A. K. Nooka, S. Sidana, D. Trancucci, R. Verona, S. Girgis, C. Uhlar, T. Stephenson, A. Banerjee, A. Krishnan

    Published 2022-06-01
    Get full text
    Article
  4. 4
    P922: HEALTH-RELATED QUALITY OF LIFE WITH TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1

    P922: HEALTH-RELATED QUALITY OF LIFE WITH TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1 by R. Popat, P. Moreau, S. Z. Usmani, A. Garfall, M.-V. Mateos, J. F. San-Miguel, A. Oriol, A. K. Nooka, L. Rosinol, A. Chari, L. Karlin, A. Krishnan, N. Bahlis, T. Martin, B. Besemer, J. Martínez-López, M. Delforge, J. Fastenau, K. S. Gries, N. W. van de Donk

    Published 2022-06-01
    Get full text
    Article
  5. 5
    P06: UPDATED RESULTS FROM THE PHASE 1/2 MAJESTEC-1 STUDY OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

    P06: UPDATED RESULTS FROM THE PHASE 1/2 MAJESTEC-1 STUDY OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOM... by R Popat, S Usmani, A Garfall, N van de Donk, H Nahi, J San-Miguel, A Oriol, A Nooka, T Martin, L Rosinol, A Chari, L Karlin, L Benboubker, M Mateos, N Bahlis, P Moreau, B Besemer, J Martínez-López, S Sidana, L Pei, D Trancucci, R Verona, S Girgis, Y Olyslager, M Jaffe, C Uhlar, T Stephenson, R Van Rampelbergh, A Banerjee, J Goldberg, R Kobos, A Krishnan

    Published 2022-04-01
    Get full text
    Article

Search Tools: